胸段硬膜外罗哌卡因与布比卡因对下尿路功能影响的随机临床试验
本研究为单中心随机双盲优效性试验,纳入42例开腹肾脏手术患者,比较胸段硬膜外0.125%布比卡因与0.2%罗哌卡因对排尿后残余尿量和最大尿流率的影响。结果显示罗哌卡因组排尿后残余尿量增加显著低于布比卡因组,最大尿流率下降也更轻,提示罗哌卡因对逼尿肌功能抑制更小。
要点
- 胸段硬膜外罗哌卡因较布比卡因显著降低排尿后残余尿量。
- 罗哌卡因组最大尿流率下降幅度更小,膀胱功能影响更轻。
- 两组疼痛评分相似,无不良事件发生。
核心结论
- 胸段硬膜外镇痛使用罗哌卡因相比布比卡因可显著降低排尿后残余尿量,反映罗哌卡因对逼尿肌功能损害更小。
研究设计与样本
- 单中心、平行组、随机、双盲优效性试验,42例开腹肾脏手术患者随机分配至0.125%布比卡因组或0.2%罗哌卡因组,最终36例纳入分析。
主要发现
- 布比卡因组排尿后残余尿量较基线中位增加300 ml(范围30至510,P<0.001),罗哌卡因组增加125 ml(范围-30至350,P=0.011),组间平均差异-175 ml(95%CI -295至-40,P=0.012)。
- 布比卡因组最大尿流率中位下降-12 ml/s(范围-28至3,P<0.001),罗哌卡因组下降-4 ml/s(范围-16至7,P=0.025),组间平均差异7 ml/s(95%CI 0至12,P=0.028)。
- 两组疼痛评分相似,未发生不良事件。
关键数值与推荐
- 纳入标准为膀胱功能正常。
- 主要结局为术前与术后胸段硬膜外镇痛期间排尿后残余尿量的差异。
- 次要结局为组间及组内最大尿流率的变化。
临床怎么用
- 对于需胸段硬膜外镇痛且关注膀胱功能的患者,罗哌卡因可能较布比卡因减少排尿后残余尿量。
局限性
- 单中心研究,最终分析样本量36例,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Thoracic epidural analgesia with bupivacaine resulted in clinically relevant postvoid residuals due to detrusor underactivity. This study aimed to compare the risk of bladder dysfunction with ropivacaine versus bupivacaine using postvoid residuals and maximum flow rates. Our hypothesis was that ropivacaine would result in lower postvoid residuals, because ropivacaine has been shown to have less effect on motor blockade. METHODS: In this single-center, parallel-group, randomized, double-blind superiority trial, 42 patients undergoing open renal surgery were equally allocated to receive epidural bupivacaine 0.125% or ropivacaine 0.2%, and 36 were finally included. Inclusion criterion was normal bladder function. Patients underwent urodynamic investigations preoperatively and during thoracic epidural analgesia. Primary outcome was the difference in postvoid residual preoperatively and during thoracic epidural analgesia postoperatively. Secondary outcomes were changes in maximum flow rate between and within the groups. RESULTS: Median difference in postvoid residual (ml) from baseline to postoperatively was 300 (range, 30 to 510; P < 0.001) for bupivacaine and 125 (range, -30 to 350; P = 0.011) for ropivacaine, with a significant mean difference between groups (-175; 95% CI, -295 to -40; P = 0.012). Median difference in maximum flow rate (ml/s) was more pronounced with bupivacaine (-12; range, -28 to 3; P < 0.001) than with ropivacaine (-4; range, -16 to 7; P = 0.025) with a significant mean difference between groups (7; 95% CI, 0 to 12; P = 0.028). Pain scores were similar. No adverse events occurred. CONCLUSIONS: Postvoid residuals were significantly lower using ropivacaine compared to bupivacaine for thoracic epidural analgesia reflecting less impairment of detrusor function with ropivacaine.
引用
- Girsberger SA, Schneider MP, Löffel LM, et al. Effect of Thoracic Epidural Ropivacaine versus Bupivacaine on Lower Urinary Tract Function: A Randomized Clinical Trial. Anesthesiology. 2018. PMID: 29189291. doi:10.1097/ALN.0000000000001980
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。